Photocure ASA · OSL:PHO
Photocure ASA — H.C. Wainwright 21st Annual Global Investment Conference 2019
23 slides from Photocure ASA's conference presentation, September 2019
Slide 1: Photocure ASA Company Presentation
PHOTOCURE ASA COMPANY PRESENTATION H.C. WAINWRIGHT 21ST ANNUAL GLOBAL INVESTMENT CONFERENCE September 2019 Daniel Schneider, President and CEO
Slide 2: Disclaimer
DISCLAIMER By reading this company presentation (the “Presentation”), or attending any meeting or oral presentation held in relation thereto, you (the “Recipient”) agree to be bound by the following terms, conditions and limitations. The Presentation has been produced by Photocure (the “Company”) fo
Slide 3: Photocure Before and Now
PHOTOCURE BEFORE AND NOW: Continue success of Hexvix®/Cysview ® Expand portfolio of New strategic focus: bladder cancer assets The Bladder Cancer Company Global Leader in 2020 + beyond Photodynamic Therapy (PDT) 2018 As of 1997 3
Slide 4: Photocure at a Glance
PHOTOCURE AT A GLANCE Oslo (HQ) Norwegian commercial-stage pharmaceutical company focused on bladder cancer Princeton (NJ) 75 Own commercial operations in Nordics and USA. Partners in Europe, Canada, Australia and New Zealand employees UNIQUE Photocure Technology® Platform of which 45 in US Used for
Slide 5: Photocure at a Glance
PHOTOCURE AT A GLANCE Oslo (HQ) Core drug-device product on market Princeton (NJ) Bladder cancer detection & management ~$140M Accelerating revenue growth Market cap +20% total revenue growth in 2018 $ 35M global in-market sales* 150K OSLO STOCK Over 500 000 patients treated EXCHANGE: Avg Daily with
Slide 6: Photocure Strategy — Four Steps
PHOTOCURE STRATEGY — FOUR STEPS TO BECOME A TRANSFORMATIVE, MULTI-PRODUCT, BLADDER CANCER COMPANY TRANSFORM ACQUIRE Build pipeline - partner/acquisitions EXPAND Expand portfolio of bladder cancer/bladder assets ACCELERATE Surveillance market New geographies Grow Cysview®/Hexvix® 6
Slide 7: Hexvix/Cysview Positioning
Hexvix®/Cysview® Positioning
Slide 8: Non-Muscle Invasive Bladder Cancer: Common with High Recurrence and Burden
NON-MUSCLE INVASIVE BLADDER CANCER IS ONE OF THE MOST COMMON CANCERS WITH SIGNIFICANT RECURRENCE RATE AND HIGH DISEASE BURDEN ~650K ~2.2M surgical procedures surveillance cystoscopies annually in USA and EU annually in USA and EU More than 60% 10% – 30% Tumor as seen through disease recurrence a cys
Slide 9: Hexvix/Cysview Addresses Need for Improved Detection and Management
HEXVIX®/CYSVIEW® ADDRESSES THE NEED FOR IMPROVED DETECTION AND MANAGEMENT OF BLADDER CANCER Clinic/Office Diagnostic cystoscopy flexible scope ~650k Operating procedures room EU/USA TURBT rigid scope ~2,2 mill Clinic/Office Symptoms procedures EU/USA Surveillance cystoscopy flexible scope Diagram ba
Slide 10: Blue Light Cystoscopy with Hexvix/Cysview: A Transformative Solution
BLUE LIGHT CYSTOSCOPY WITH HEXVIX®/CYSVIEW®? A TRANSFORMATIVE SOLUTION TO IMPROVE THE LIVES OF PATIENTS WITH BLADDER CANCER Key benefits • Improved Patient outcomes (diagnostic accuracy + surgical results) • Significant reduction of disease recurrence • Reduction in disease progression • Improved co
Slide 11: Blue Light Cystoscopy with Hexvix/Cysview
Key feature BLUE LIGHT CYSTOSCOPY WITH HEXVIX®/CYSVIEW® Better visual contrast between benign and malignant cells Blue Light Cystoscopy (BLC™) with Hexvix/Cysview is a drug and device combination for better detection and management of NMIBC. Hexvix/Cysview is a Hexvix/Cysview is used with pharmaceut
Slide 12: Positioned for growth
Positioned for growth
Slide 13: Accelerated Momentum: Consecutive Quarters of Record US Revenues
ACCELERATED MOMENTUM 6 CONSECUTIVE QUARTERS OF RECORD REVENUES IN US US (1000 NOK) 30000 25000 20000 15000 10000 5000 0 13 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19
Slide 14: Accelerated Momentum: Installed Base of Cystoscopes in the US
ACCELERATED MOMENTUM INSTALLED BASE OF CYSTOSCOPES IN THE US 200 188 180 171 157 160 140 120 104 100 83 80 65 60 51 40 36 25 20 2012 2013 2014 2015 2016 2017 2018 Q1 2019 Q2 2019 0
Slide 15: Supportive Environment & Increasing Awareness
SUPPORTIVE ENVIRONMENT & INCREASING AWARENESS FOR BECOMING THE STANDARD OF CARE FOR THE DETECTION AND MANAGEMENT OF BLADDER CANCER • Inclusion in Bladder Cancer treatment guidelines BLC™ with Hexvix® /Cysview® is strongly recommended by US, European and national guidelines as well as expert panels.
Slide 16: Hexvix/Cysview – Key Enablers in Place and Ready for Growth
HEXVIX®/CYSVIEW® – KEY ENABLERS IN PLACE AND READY FOR GROWTH Penetration Position in the life cycle Key success factors 100% Approval – surgical & surveillance 75% Denmark Acceptance – major & local guidelines 50% Access – Permanent and favorable Nordic reimbursement “Activated” Awareness – Patient
Slide 17: Cevira License Agreement
Cevira® License Agreement
Slide 18: Cevira: License Agreement with Asieris
CEVIRA®: LICENSE AGREEMENT WITH ASIERIS ASIERIS MEDITECH CO., • Asieris is a subsidiary of the China-based • Its leading drug candidate, an oral drug for Ltd. Jiangsu Yahong Meditech Co., Ltd., a treating non-muscle invasive bladder specialty pharma company fully committed cancer, is in a registrati
Slide 19: Cevira: Terms of License Agreement with Asieris
CEVIRA®: TERMS OF LICENSE AGREEMENT WITH ASIERIS TERMS OF THE LICENSING AGREEMENT* • Under the License Agreement, Photocure will receive a total signing fee of USD 5 million within 6 months after signing. • Approval of the initial indication will result in USD 18 million in China and USD 36 million
Slide 20: Financials
Financials — ae
Slide 21: Segment Performance Second Quarter 2019
SEGMENT PERFORMANCE SECOND QUARTER 2019 Commercial Franchise Amounts in USD million Q2 ’19 Q2 ‘18 Change YTD ‘19 YTD ‘18 Change • Continued strong revenue growth in US, YTD Commercial Franchise revenue growth 46% Nordic revenue 1.2 1.3 -8% 2.8 2.9 -4% – Installed base of rigid and flex BLC 171 at qu
Slide 22: Summary and Outlook
Summary and Outlook — ——
Slide 23: Photocure Strategy — Four Steps
PHOTOCURE STRATEGY — FOUR STEPS TO BECOME A TRANSFORMATIVE, MULTI-PRODUCT, BLADDER CANCER COMPANY TRANSFORM ACQUIRE Build pipeline - partner/acquisitions EXPAND Expand portfolio of bladder cancer/bladder assets ACCELERATE Surveillance market New geographies 2020 revenue outlook of 20-25M$ in the US
Photocure — H.C. Wainwright 21st Annual Global Investment Conference 2019 on 6ix